Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $8.99 billion. The enterprise value is $7.83 billion.
| Market Cap | 8.99B |
| Enterprise Value | 7.83B |
Important Dates
The last earnings date was Monday, August 3, 2026, after market close.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 106.07 million shares outstanding. The number of shares has increased by 11.25% in one year.
| Current Share Class | 106.07M |
| Shares Outstanding | 106.07M |
| Shares Change (YoY) | +11.25% |
| Shares Change (QoQ) | +1.40% |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 96.44% |
| Float | 95.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 213.19 |
| Forward PS | 103.12 |
| PB Ratio | 7.52 |
| P/TBV Ratio | 7.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 185.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.57, with a Debt / Equity ratio of 0.04.
| Current Ratio | 15.57 |
| Quick Ratio | 15.24 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.45% and return on invested capital (ROIC) is -27.89%.
| Return on Equity (ROE) | -42.45% |
| Return on Assets (ROA) | -26.28% |
| Return on Invested Capital (ROIC) | -27.89% |
| Return on Capital Employed (ROCE) | -44.21% |
| Weighted Average Cost of Capital (WACC) | 4.71% |
| Revenue Per Employee | $70,970 |
| Profits Per Employee | -$844,455 |
| Employee Count | 594 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CRNX has paid $180,000 in taxes.
| Income Tax | 180,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +175.90% in the last 52 weeks. The beta is 0.09, so CRNX's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +175.90% |
| 50-Day Moving Average | 64.79 |
| 200-Day Moving Average | 48.33 |
| Relative Strength Index (RSI) | 90.53 |
| Average Volume (20 Days) | 2,440,111 |
Short Selling Information
The latest short interest is 5.87 million, so 5.53% of the outstanding shares have been sold short.
| Short Interest | 5.87M |
| Short Previous Month | 6.21M |
| Short % of Shares Out | 5.53% |
| Short % of Float | 6.14% |
| Short Ratio (days to cover) | 0.75 |
Income Statement
In the last 12 months, CRNX had revenue of $42.16 million and -$501.61 million in losses. Loss per share was -$5.03.
| Revenue | 42.16M |
| Gross Profit | -334.72M |
| Operating Income | -549.09M |
| Pretax Income | -501.43M |
| Net Income | -501.61M |
| EBITDA | -544.85M |
| EBIT | -549.09M |
| Loss Per Share | -$5.03 |
Balance Sheet
The company has $1.21 billion in cash and $47.19 million in debt, with a net cash position of $1.16 billion or $10.92 per share.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 47.19M |
| Net Cash | 1.16B |
| Net Cash Per Share | $10.92 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 11.27 |
| Working Capital | 1.16B |
Cash Flow
In the last 12 months, operating cash flow was -$422.52 million and capital expenditures -$2.66 million, giving a free cash flow of -$425.18 million.
| Operating Cash Flow | -422.52M |
| Capital Expenditures | -2.66M |
| Depreciation & Amortization | 4.24M |
| Net Borrowing | n/a |
| Free Cash Flow | -425.18M |
| FCF Per Share | -$4.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,302.52% |
| Pretax Margin | -1,189.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.25% |
| Shareholder Yield | -11.25% |
| Earnings Yield | -5.58% |
| FCF Yield | -4.73% |
Analyst Forecast
The average price target for CRNX is $85.50, which is 0.89% higher than the current price. The consensus rating is "Hold".
| Price Target | $85.50 |
| Price Target Difference | 0.89% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 283.00% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 16.07 and a Piotroski F-Score of 3.
| Altman Z-Score | 16.07 |
| Piotroski F-Score | 3 |